JSM 6427 - α5β1 Integrin Antagonist

Novel therapeutic approach in AMD and oncology

• JSM 6427 targets α5β1 integrin for treatment of age-related macular degeneration (AMD)
• October 2007, first patient treated in Phase I clinical trial for AMD
• Targeting α5β1 integrin represents a new therapeutic approach by addressing different modes of action
• JSM 6427 addresses angiogenesis (induced by multiple growth factors), inflammation and fibrosis
• α5β1 integrin antagonist's mutiple mode of action offers a promising new approach to oncology
  

Integrin for the Treatment of AMD and other Indications

JSM-7717 & JPE-1375
- C5a Receptor Antagonists

Inflammatory and ophthalmological diseases

• C5a receptor antagonists, JSM-7717 and JPE-1375, are in development for the treatment of inflammatory and ophthalmological indications and have shown positive preclinical results.

C5aRA - Controlling Inflammation

JSM 10292
- Bradykinin B2 Receptor Antagonist

The Next Generation B2 Receptor Antagonist

• Jerini has begun the development of an orally-available small molecule bradykinin B2 receptor antagonist compound to treat chronic and acute disease indications.

More information on JSM 10292

Bradykinin B1 Receptor Antagonist

Development of an antagonist of the inducible B1 Receptor

Jerini is developing an orally-available small molecule bradykinin B1 receptor antagonist to treat conditions associated with inflammation and/or pain.

Read more